Nifty Pharma Index Gains Nearly 1% After Fed Cuts Interest Rates

The Nifty Pharma index gained nearly 1% in the afternoon due to the US Federal Reserve’s decision to cut interest rates by 25 basis points. This move has encouraged investor confidence and led to increased buying interest among pharma stocks.
How Does the Fed Rate Cut Impact India’s Pharma Industry?
The Federal Reserve’s rate cut is aimed at supporting the US economy but has global effects. For India, lower US interest rates often attract more foreign investment in the pharmaceutical industry. This means more money flows into Indian markets, which can strengthen the rupee and push up stock prices.
Nifty Pharma Index Gains Nearly 1% on Thursday
Following the announcement, the Nifty Pharma index rose by 0.70%, reaching 22,398.15 points by midday. Key pharma stocks showed impressive gains:
| Company | LTP | % Change |
| Natco Pharma | 881.25 | 2.80% |
| Biocon | 360.80 | 1.82% |
| Glenmark Pharma | 2,078.60 | 1.77% |
| Ipca Laboratories | 1,327.70 | 1.26% |
| Sun Pharma | 1,638.80 | 1.15% |
What It Means for Investors
The Fed’s rate cut makes Indian pharma stocks more attractive as foreign investors seek higher returns. A stronger rupee and easier access to funds may help pharmaceutical companies expand and improve profitability. This is a positive sign for investors with a demat account looking for growth opportunities in this sector.
Read more: Don’t Pay More Before Sept 22, 2025! Here are 14 FAQs For Buyers For Understanding GST 2.0.
Conclusion
The US Federal Reserve’s interest rate cut has given a clear boost to the Indian pharmaceutical sector. The Nifty Pharma index and top companies have responded well, signalling improved confidence and growth potential in the sector amid rising foreign investments and a strengthening rupee.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.
Published on: Sep 18, 2025, 12:49 PM IST

- Stocks to Watch Today: PB Fintech, Voltas, Juniper Green Energy and Others in Focus (August 17, 2026)
- NSE Clearing To Launch R3 Series for Shorter-Tenure SLB Contracts From August 17, 2026
- Sony Pictures India To Enter Tamil GEC Market With Sony VIZHA in October 2026
- SEBI Proposes Colour-Coded Credit Risk-o-Meter for Debt Securities
- Hinduja Group Signs MoU for ₹2,500 Crore Investment in Tamil Nadu


